Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Pharmacology, Toxicology and Pharmaceutical Science
8
3%
Other
28
12%
Unknown
113
49%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 July 2026.
All research outputs
#1,438,119
of 34,601,305 outputs
Outputs from Lancet Neurology
#938
of 4,660 outputs
Outputs of similar age
#24,926
of 488,932 outputs
Outputs of similar age from Lancet Neurology
#17
of 55 outputs
Altmetric has tracked 34,601,305 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,660 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.4. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 488,932 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
